#France #Servier #Suresnes #DAY ONE #OJEMDA

Servier Completes Acquisition of Day One Biopharmaceuticals

Servier, a globally recognized independent pharmaceutical group based in France, has announced the completion of its acquisition of Day One Biopharmaceuticals, a company focused on developing targeted therapies for severe illnesses affecting people across all ages. This strategic move, valued at approximately $2.5 billion, highlights Servier's commitment to expanding its oncology portfolio, particularly in the area of low-grade glioma, a common brain tumor found in children.

Details of the Transaction

The acquisition was executed through a successful tender offer for all outstanding shares of Day One Biopharmaceuticals (Nasdaq: DAWN), with an offering price of $21.50 per share. This deal effectively places Day One under the Servier umbrella, granting the company immediate access to Day One’s advanced pipeline and FDA-approved products, notably OJEMDA (tovorafenib), which is aimed at treating pediatric low-grade glioma.

Olivier Laureau, the President of Servier, emphasized the importance of this acquisition in aligning with the company's 2030 ambitions to bolster its presence in rare cancers. He stated, "Integrating Day One's scientific and clinical capabilities will enhance our Group's ability to support long-term innovation and translate science into meaningful medicines for children and families affected by rare cancers."

Strengthening the Oncology Pipeline

Alongside the commercially available OJEMDA product, which is currently marketed in the United States, the acquisition enriches Servier's oncology pipeline encompassing early clinical to Phase 3 assets targeting rare cancers. Notable among these is Emi-Le (emiltatug ledadotin), an innovative antibody-drug conjugate, along with DAY301, a targeted therapeutic approach specifically designed for rare malignancies.

David K. Lee, Executive Vice President of Servier Pharmaceuticals in the USA, remarked on the significance of acquiring Day One, stating, "This acquisition marks an important next chapter in how we expand our presence in oncology in the U.S. and fortify our ability to deliver meaningful outcomes to patients. With Day One, we are not just gaining an approved medicine but also inheriting strong scientific acumen paired with an experienced team dedicated to innovation in patient care."

Implications for Patient Care

This acquisition signals a robust commitment to meeting the urgent needs of patients grappling with rare cancers. By aligning its resources with Day One's expertise, Servier aims to make significant advancements in treatment options available to pediatric patients, thereby enhancing the quality of care.

With both companies sharing a vision focused on patient-centered outcomes, the partnership is expected to catalyze further innovations and broaden the spectrum of effective therapies for those dealing with critical health challenges. Servier is poised to make substantial contributions to the oncology landscape, ultimately benefiting patients and families affected by these demanding conditions.

In conclusion, Servier's acquisition of Day One Biopharmaceuticals is a strategic advancement towards reinforcing its foothold in the oncology sector, particularly in providing accessible and specialized therapies for rare cancers impacting children. Seamlessly blending their resources and expertise, both establishments strive to reshape the future of oncology treatment through innovation and sustained patient support.